Astera Labs Inc’s recently made public that its Officer Tate Michael Truett acquired Company’s shares for reported $1.65 million on Nov 17 ’25. In the deal valued at $144.34 per share,11,430 shares were bought.
Then, Mazzara Philip bought 4,620 shares, generating $666,851 in total proceeds.
Before that, Gajendra Sanjay bought 90,459 shares. Astera Labs Inc shares valued at $13,056,852 were divested by the Officer at a price of $144.34 per share.
Northland Capital upgraded its Astera Labs Inc [ALAB] rating to an Outperform from a a Market perform in a research note published recently. A number of analysts have revised their coverage, including TD Cowen’s analysts, who remained covering the stock and in early November has reiterated a ‘”a Hold”‘ rating for it. Stifel also remained covering ALAB and reiterated its “Buy” recommendation on November 05, 2025. Needham maintained its rating on November 05, 2025. It rated ALAB as “a Buy”.
Price Performance Review of ALAB
On Monday, Astera Labs Inc [NASDAQ:ALAB] saw its stock fall -2.04% to $141.39. Over the last five days, the stock has lost -18.62%. Astera Labs Inc shares have risen nearly 58.33% since the year began. Nevertheless, the stocks have risen 6.75% over the past one year. While a 52-week high of $262.90 was reached on 09/18/25, a 52-week low of $47.12 was recorded on 04/04/25.
Levels Of Support And Resistance For ALAB Stock
The 24-hour chart illustrates a support level at 136.72, which if violated will result in even more drops to 132.04. On the upside, there is a resistance level at 146.78. A further resistance level may holdings at 152.16.
How much short interest is there in Astera Labs Inc?
A steep rise in short interest was recorded in Astera Labs Inc stocks on 2025-10-31, dropping by -0.59 million shares to a total of 8.4 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 8.99 million shares. There was a decline of -7.03%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 05, 2025 when JP Morgan resumed its ‘”an Overweight”‘ rating for the stock and retained the price target to $215.
